Technology
AbTis Linker
AbTis next generation linker
Site-specific (Fc region) conjugation using traceless linker
AbTis ADC production by Traceless Linker
(Two simple steps)
- Antibody-FcBP w/ functional group reaction
(FcBP release in this step)
- Drug w/functional group Addition (Addition of drug-linker)
AbTis ADC Linker Competitive Edge
Advantage over conventional ADC
Drug Conjugation to the unmodified mAb
- Applicable to the therapeutic antibody with no modification :
Cost-effective ADC production
Site-specific conjugation
- Covalent bond with Fc-domain
- High yield of conjugation and simple process of purification: CMC advantage
Diversity of conjugates
- Drug-loading control (1~4)
- Diverse drug conjugation / in-vivo diagnostics
Stable in serum, protease-specific drug release linker
- Peptide linker with serum stability
- Valine-Citrulline moiety
